BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jiang W, Xiang L, Pei X, He T, Shen X, Wu X, Yang H. Mutational analysis of KRAS and its clinical implications in cervical cancer patients. J Gynecol Oncol 2018;29:e4. [PMID: 29185262 DOI: 10.3802/jgo.2018.29.e4] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
Number Citing Articles
1 Fleischmann M, Chatzikonstantinou G, Fokas E, Wichmann J, Christiansen H, Strebhardt K, Rödel C, Tselis N, Rödel F. Molecular Markers to Predict Prognosis and Treatment Response in Uterine Cervical Cancer. Cancers (Basel) 2021;13:5748. [PMID: 34830902 DOI: 10.3390/cancers13225748] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
2 de Mey S, Dufait I, De Ridder M. Radioresistance of Human Cancers: Clinical Implications of Genetic Expression Signatures. Front Oncol 2021;11:761901. [PMID: 34778082 DOI: 10.3389/fonc.2021.761901] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Kuno I, Takayanagi D, Asami Y, Murakami N, Matsuda M, Shimada Y, Hirose S, Kato MK, Komatsu M, Hamamoto R, Okuma K, Kohno T, Itami J, Yoshida H, Shiraishi K, Kato T. TP53 mutants and non-HPV16/18 genotypes are poor prognostic factors for concurrent chemoradiotherapy in locally advanced cervical cancer. Sci Rep 2021;11:19261. [PMID: 34584128 DOI: 10.1038/s41598-021-98527-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
4 Choi S, Kim SW, Kim HS. Invasive Stratified Mucin-producing Carcinoma (ISMC) of the Uterine Cervix: Clinicopathological and Molecular Characteristics With Special Emphasis on the First Description of Consistent Programmed Death-ligand 1 (PD-L1) Over-expression. Cancer Genomics Proteomics 2021;18:685-98. [PMID: 34479920 DOI: 10.21873/cgp.20290] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Dass SA, Selva Rajan R, Tye GJ, Balakrishnan V. The potential applications of T cell receptor (TCR)-like antibody in cervical cancer immunotherapy. Hum Vaccin Immunother 2021;17:2981-94. [PMID: 33989511 DOI: 10.1080/21645515.2021.1913960] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Sharmin S, Zohura FT, Islam MS, Shimonty A, Khan MA, Parveen R, Sharmin F, Ahsan CR, Islam ABMMK, Yasmin M. Mutational profiles of marker genes of cervical carcinoma in Bangladeshi patients. BMC Cancer 2021;21:289. [PMID: 33736612 DOI: 10.1186/s12885-021-07906-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Mustachio LM, Chelariu-Raicu A, Szekvolgyi L, Roszik J. Targeting KRAS in Cancer: Promising Therapeutic Strategies. Cancers (Basel) 2021;13:1204. [PMID: 33801965 DOI: 10.3390/cancers13061204] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 8.0] [Reference Citation Analysis]
8 Patrono MG, Calvo MF, Franco JVA, Garrote V, Vietto V. A systematic review and meta-analysis of the prevalence of therapeutic targets in cervical cancer. Ecancermedicalscience 2021;15:1200. [PMID: 33889209 DOI: 10.3332/ecancer.2021.1200] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Bosse T, Lax S, Abu-Rustum N, Matias-Guiu X. The Role of Predictive Biomarkers in Endocervical Adenocarcinoma: Recommendations From the International Society of Gynecological Pathologists. Int J Gynecol Pathol 2021;40:S102-10. [PMID: 33570867 DOI: 10.1097/PGP.0000000000000755] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
10 Watanabe T, Nanamiya H, Kojima M, Nomura S, Furukawa S, Soeda S, Tanaka D, Isogai T, Imai JI, Watanabe S, Fujimori K. Clinical implication of oncogenic somatic mutations in early-stage cervical cancer with radical hysterectomy. Sci Rep 2020;10:18734. [PMID: 33127935 DOI: 10.1038/s41598-020-72518-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
11 Yoshimoto Y, Sasaki Y, Murata K, Noda SE, Miyasaka Y, Hamamoto J, Furuya M, Hirato J, Suzuki Y, Ohno T, Tokino T, Oike T, Nakano T. Mutation profiling of uterine cervical cancer patients treated with definitive radiotherapy. Gynecol Oncol 2020;159:546-53. [PMID: 32951893 DOI: 10.1016/j.ygyno.2020.08.020] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
12 Uprety D, Adjei AA. KRAS: From undruggable to a druggable Cancer Target. Cancer Treatment Reviews 2020;89:102070. [DOI: 10.1016/j.ctrv.2020.102070] [Cited by in Crossref: 64] [Cited by in F6Publishing: 58] [Article Influence: 21.3] [Reference Citation Analysis]
13 Alcantara KMM, Malapit JRP, Yu RTD, Garrido JAMG, Rigor JPT, Angeles AKJ, Cutiongco-de la Paz EM, Garcia RL. Non-Redundant and Overlapping Oncogenic Readouts of Non-Canonical and Novel Colorectal Cancer KRAS and NRAS Mutants. Cells 2019;8:E1557. [PMID: 31816869 DOI: 10.3390/cells8121557] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
14 Hirose S, Murakami N, Takahashi K, Kuno I, Takayanagi D, Asami Y, Matsuda M, Shimada Y, Yamano S, Sunami K, Yoshida K, Honda T, Nakahara T, Watanabe T, Komatsu M, Hamamoto R, Kato MK, Matsumoto K, Okuma K, Kuroda T, Okamoto A, Itami J, Kohno T, Kato T, Shiraishi K, Yoshida H. Genomic alterations in STK11 can predict clinical outcomes in cervical cancer patients. Gynecol Oncol 2020;156:203-10. [PMID: 31757465 DOI: 10.1016/j.ygyno.2019.10.022] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
15 Akagi Y, Tachibana T, Orita Y, Gion Y, Marunaka H, Makino T, Miki K, Akisada N, Yoshino T, Nishizaki K, Sato Y. KRAS mutations in tongue squamous cell carcinoma. Acta Otolaryngol 2019;139:647-51. [PMID: 31066593 DOI: 10.1080/00016489.2019.1610574] [Reference Citation Analysis]
16 Xiang L, Jiang W, Ye S, He T, Pei X, Li J, Chan DW, Ngan HYS, Li F, Tao P, Shen X, Zhou X, Wu X, Yang G, Yang H. ERBB2 mutation: A promising target in non-squamous cervical cancer. Gynecol Oncol 2018;148:311-6. [PMID: 29279289 DOI: 10.1016/j.ygyno.2017.12.023] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]